NanoVibronix Shares Rocket 67% After Delayed Q2 Filing and Ultrasound Device Clearances

Introduction

NanoVibronix Inc. (NASDAQ: NAOV) is a medical device company headquartered in Elmsford, New York, with research and development operations in Nesher, Israel. The company utilizes proprietary low-intensity, surface acoustic wave ultrasound technology to design patch-based and catheter-based devices, including PainShield®, WoundShield™, and UroShield™, which deliver localized therapeutic ultrasound as alternatives for pain management, wound healing, and infection prevention.

Corporate Structure

NanoVibronix maintains a workforce of approximately 11 to 50 employees. Its executive team includes Chief Executive Officer Brian Murphy, who has served since October 2016, Chief Financial Officer Steve Brown, who was reappointed on October 5, 2020, and Chief Medical Officer Dr. Harold Jacob, who has been in office since March 1, 2014. The board of directors is chaired by Chris Fashek, and founder Jona Zumeris, Ph.D., plays a significant role in the company’s technology strategy.

Ultrasound Therapy by Rosa Rafael

Recent Developments and News

• On August 14, 2025, NanoVibronix filed a Form NT 10-Q with the U.S. Securities and Exchange Commission, notifying investors of a delay in the filing of its quarterly report.
• The company submitted its Quarterly Report on Form 10-Q for the period ended June 30, 2025, on August 19, 2025.
• On September 15, 2025, shares of NAOV closed at $10.88, reflecting an increase of 67.64% from the prior close of $6.49, with a trading volume of 4,198,921 shares.
• Regulatory certifications for PainShield and WoundShield include CE Mark approval, and PainShield also carries FDA clearance. UroShield and NG-Shield devices retain CE Mark certification.

Financial and Strategic Analysis

As per its most recent U.S. SEC disclosures, NanoVibronix reported trailing-twelve-month (TTM) revenue of $2.34 million and TTM EBITDA of $7.79 million. The company’s gross margin stands at 32.07%, while its net loss margin is 380.29%. Key financial ratios include a forward P/E of 32.45 and a debt-to-equity ratio of 4.88%. With approximately 797,000 shares outstanding, its market capitalization is approximately $5.17 million. NanoVibronix continues to invest in research and development to enhance its ultrasound platform, targeting prescription-based therapeutic applications and exploring potential strategic partnerships to broaden market access.

Market Position and Industry Context

NanoVibronix operates within the medical equipment manufacturing sector, focusing on therapeutic ultrasound and infection prevention devices. Its low-intensity acoustic technology addresses pain therapy, wound care, and catheter-associated urinary tract infection prevention. The therapeutic ultrasound market is evolving as healthcare providers seek device-based treatment alternatives. NanoVibronix competes with established ultrasound manufacturers and companies that offer catheter coatings or antimicrobial solutions. Its unique platform of wearable and catheter-based transducers is positioned to capture specific segments in outpatient care and infection control environments.

tl;dr

On September 15, 2025, NanoVibronix shares increased by 67.64% to close at $10.88 following the August 19, 2025 filing of its Q2 Form 10-Q after a five-day extension notice. The company reported TTM revenue of $2.34 million and EBITDA of $7.79 million, maintaining CE Mark and FDA clearances for its PainShield, WoundShield, UroShield, and NG-Shield devices. Upcoming developments include detailed Q2 financial results, ongoing research and development initiatives, and potential strategic partnerships to expand its low-intensity therapeutic ultrasound offerings.